Elanco Animal Health
ELAN
22.36
-0.12
-0.53%
Elanco Animal Health
US · ELAN
#1381 by market cap
Listed 2018
22.36
-0.12
-0.53%
Live - 5344 symbols - heartbeat 149s ago
· 2026-10-08 08:30
Pre-market
22.09
-1.21%
After-hours
22.27
-0.40%
- Market cap
- 11.17B
- P/E (TTM)i
- -54.54
- P/Bi
- 1.70
- EPSi
- -0.47
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on ELAN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.34, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.22% YoY
Margins
- Gross margin
- 54.99%
- Operating margin
- 5.34%
- Net margin
- -4.92%
Key ratios & quality
- Enterprise valuei
- 14.64B
- Altman Z-Scorei
- 1.34
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.07B | 3.07B | 3.27B | 4.76B | 4.41B | 4.42B | 4.44B | 4.72B |
| Gross profit | 1.49B | 1.60B | 1.60B | 2.63B | 2.50B | 2.49B | 2.44B | 2.59B |
| Selling & admin expenses | 735.20M | 760.00M | 997.00M | 1.40B | 1.27B | 1.29B | 1.31B | 1.43B |
| Research & development | 246.60M | 270.00M | 329.00M | 369.00M | 321.00M | 327.00M | 344.00M | 368.00M |
| Operating profit | 313.80M | 371.00M | -82.00M | 304.00M | 384.00M | 326.00M | 251.00M | 252.00M |
| Pretax profit | 114.10M | 78.00M | -677.00M | -571.00M | -72.00M | -1.20B | 488.00M | -224.00M |
| Tax | 27.60M | 10.00M | -103.00M | -88.00M | 6.00M | 36.00M | 150.00M | 8.00M |
| Net profit | 86.50M | 68.00M | -574.00M | -483.00M | -78.00M | -1.23B | 338.00M | -232.00M |
| Basic EPS | 0 | 0 | -1 | -1 | 0 | -3 | 1 | 0 |
| Diluted EPS | 0.28 | 0.18 | -1.30 | -0.99 | -0.16 | -2.50 | 0.68 | -0.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.19B | 1.24B | 1.14B | 1.14B | 1.37B | 1.37B |
| Gross profit | 684.00M | 713.00M | 607.00M | 589.00M | 785.00M | 798.00M |
| Selling & admin expenses | 341.00M | 400.00M | 351.00M | 338.00M | 381.00M | 449.00M |
| Research & development | 94.00M | 92.00M | 89.00M | 93.00M | 97.00M | 92.00M |
| Operating profit | 121.00M | 85.00M | 27.00M | 19.00M | 169.00M | 118.00M |
| Pretax profit | 60.00M | 25.00M | -50.00M | -259.00M | 87.00M | 56.00M |
| Tax | -7.00M | 14.00M | -16.00M | 17.00M | 30.00M | 2.00M |
| Net profit | 67.00M | 11.00M | -34.00M | -276.00M | 57.00M | 54.00M |
| Basic EPS | 0 | 0 | 0 | -1 | 0 | 0 |
| Diluted EPS | 0.13 | 0.02 | -0.07 | -0.56 | 0.11 | 0.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.50B | 2.37B | 3.42B | 3.27B | 3.28B | 3.41B | 3.22B | 3.46B |
| Cash & ST investments | 474.80M | 334.00M | 495.00M | 638.00M | 345.00M | 352.00M | 468.00M | 545.00M |
| Inventory | 1.00B | 1.05B | 1.58B | 1.37B | 1.54B | 1.74B | 1.57B | 1.74B |
| Total assets | 8.96B | 8.99B | 17.69B | 16.48B | 15.49B | 14.36B | 12.61B | 13.36B |
| Total current liabilities | 970.70M | 818.50M | 2.08B | 1.65B | 1.70B | 1.24B | 1.32B | 1.60B |
| Short-term debt | 29.00M | 24.50M | 555.00M | 294.00M | 388.00M | 38.00M | 44.00M | 74.00M |
| Long-term debt | 2.44B | 2.33B | 5.57B | 6.03B | 5.45B | 5.74B | 4.28B | 3.94B |
| Total liabilities | 3,759,200,000.00 | 3,438,900,000.00 | 9,217,000,000.00 | 8,970,000,000.00 | 8,202,000,000.00 | 8,139,000,000.00 | 6,518,000,000.00 | 6,811,000,000.00 |
| Total equity | 5.20B | 5.55B | 8.48B | 7.51B | 7.29B | 6.22B | 6.10B | 6.55B |
| Retained earnings | 16.40M | 84.30M | -477.00M | -979.00M | -1.06B | -2.29B | -1.95B | -2.18B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.44B | 3.61B | 3.49B | 3.46B | 3.58B | 3.80B |
| Cash & ST investments | 487.00M | 539.00M | 505.00M | 545.00M | 428.00M | 530.00M |
| Inventory | 1.59B | 1.67B | 1.71B | 1.74B | 1.72B | 1.77B |
| Total assets | 12.94B | 13.74B | 13.55B | 13.36B | 13.22B | 13.56B |
| Total current liabilities | 1.27B | 1.39B | 1.46B | 1.60B | 1.66B | 1.85B |
| Short-term debt | 44.00M | 61.00M | 62.00M | 74.00M | 73.00M | 73.00M |
| Long-term debt | 4.35B | 4.15B | 3.96B | 3.94B | 3.92B | 3.85B |
| Total liabilities | 6,588,000,000.00 | 6,967,000,000.00 | 6,802,000,000.00 | 6,811,000,000.00 | 6,722,000,000.00 | 6,973,000,000.00 |
| Total equity | 6.35B | 6.78B | 6.75B | 6.55B | 6.50B | 6.59B |
| Retained earnings | -1.88B | -1.87B | -1.91B | -2.18B | -2.13B | -2.07B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 487.30M | 224.00M | -41.00M | 483.00M | 452.00M | 271.00M | 541.00M | 560.00M |
| Depreciation & amortization | 296.00M | 314.00M | 517.00M | 716.00M | 682.00M | 694.00M | 662.00M | 680.00M |
| Free cash flow | 350.80M | 27.00M | -352.00M | 286.00M | 268.00M | 131.00M | 394.00M | 284.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.66B | 0 | 1.22B | -- | -- | -- | -- | -- |
| Ending cash balance | 677.50M | 345.00M | 506.00M | 638.00M | 345.00M | 352.00M | 468.00M | 545.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.00M | 237.00M | 219.00M | 108.00M | 13.00M | 277.00M |
| Depreciation & amortization | 161.00M | 169.00M | 176.00M | 174.00M | 172.00M | 171.00M |
| Free cash flow | -69.00M | 180.00M | 127.00M | 46.00M | -38.00M | 244.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -13.00M | -1.00M | -- | -- | -34.00M | -1.00M |
| Ending cash balance | 487.00M | 539.00M | 505.00M | 545.00M | 428.00M | 530.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 1.33 | 1.26 | -7.99 | -5.89 | -1.05 | -18.22 | 5.49 | -3.67 |
| ROA %i | 0.97 | 0.76 | -4.20 | -2.76 | -0.49 | -8.25 | 2.51 | -1.79 |
| ROIC %i | 1.22 | 1.75 | -3.87 | -1.94 | 0.83 | -8.06 | 4.46 | -0.55 |
| 5-year avg ROE %i | -- | -- | -2.09 | -3.17 | -2.54 | -6.45 | -5.60 | -4.70 |
| EBIT margin %i | 4.69 | 5.12 | -15.95 | -6.95 | 3.83 | -20.78 | 16.29 | -0.08 |
| FCF / sales %i | 11.50 | 0.87 | -- | 6.00 | 6.08 | 2.65 | 8.56 | 6.02 |
| Current ratioi | 2.58 | 2.90 | 1.65 | 1.99 | 1.93 | 2.75 | 2.44 | 2.17 |
| Quick ratioi | 1.22 | 1.50 | 0.76 | 1.01 | 0.79 | 1.10 | 1.03 | 0.93 |
| Debt / assetsi | 27.60 | 26.21 | 34.63 | 38.35 | 37.67 | 40.20 | 34.26 | 30.07 |
| LT debt / equityi | 47.01 | 42.01 | 65.74 | 80.25 | 74.74 | 92.17 | 70.16 | 60.23 |
| Interest coveragei | 4.85 | 1.99 | -3.49 | -1.40 | 0.70 | -3.31 | 3.08 | -0.02 |
| Revenue CAGR (3Y) %i | 1.78 | 1.77 | 4.23 | 15.81 | 12.83 | 10.53 | -2.33 | 2.25 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -16.03 | -- | -6.58 | 114.91 | -- | 11.27 | 1.95 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 6.01 | 6.83 | 0.54 | -3.67 | -3.77 | -2.98 |
| ROA %i | 2.77 | 3.16 | 0.27 | -1.79 | -1.85 | -1.46 |
| ROIC %i | 4.59 | 5.08 | 1.69 | -0.55 | -0.94 | -0.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.83 | 17.51 | 3.70 | -0.08 | 0.82 | 1.63 |
| FCF / sales %i | 7.52 | 7.74 | 7.71 | 6.02 | 6.44 | 7.55 |
| Current ratioi | 2.71 | 2.60 | 2.40 | 2.17 | 2.16 | 2.05 |
| Quick ratioi | 1.22 | 1.18 | 1.02 | 0.93 | 0.95 | 0.91 |
| Debt / assetsi | 33.96 | 30.63 | 29.70 | 30.07 | 30.18 | 28.89 |
| LT debt / equityi | 68.49 | 61.23 | 58.71 | 60.23 | 60.28 | 58.36 |
| Interest coveragei | 3.56 | 4.09 | 0.91 | -0.02 | 0.17 | 0.33 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development, manufacturing, marketing and sales of animal health products for both pets and farm100.00%
Quote time 2026-10-08 08:30:09 · For reference only, not investment advice and not tailored to your situation.